Compare Oatly Group AB - ADR (OTLY) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oatly Group AB - ADR vs GeneDx Holdings Corp — how do they compare? Oatly Group AB - ADR trades at $10.42 (market cap $330.93M), while GeneDx Holdings Corp trades at $67.52 (market cap $2.02B). The key difference: GeneDx Holdings Corp is far larger — about 6.1× Oatly Group AB - ADR's market cap, and GeneDx Holdings Corp is more actively traded (734,640 versus 68,708). Which is the better fit depends on your goals — on Pluang, investors hold Oatly Group AB - ADR for 18 Days and GeneDx Holdings Corp for 19 Days on average.
| OTLY | WGS | |
|---|---|---|
Market Cap | $330.93M | $2.02B |
Volume | 68,708 | 734,640 |
Sector | Consumer Staples | Health |
52-Week High | $15.91 | $167.51 |
52-Week Low | $8.03 | $34.51 |
Typical Hold Time | 18 Days | 19 Days |
Enterprise Value | $835.34M | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OTLY trades at $10.37, down 1.33% today, with a mixed technical picture showing bearish moving averages but oversold RSI readings. Fundamentally, the company shows improving revenue growth ($862M in 2025, projected $925M in 2026) and narrowing losses, though it remains unprofitable with negative cash flow. Analyst sentiment is divided with a $12.28 consensus target, representing 18% upside potential from current levels.
The outlook suggests cautious optimism as Oatly demonstrates operational improvements and revenue acceleration, but significant risks remain including persistent negative cash flow, high debt levels, and competitive pressures in the plant-based beverage market. The stock offers potential for recovery if the company can achieve its projected path toward profitability.
GeneDx (WGS) trades at $68.50, down 0.04% with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue of $114.4M beating expectations but net income margin remains negative at -23.4%. Recent developments include new product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus targets $81.00 (18% upside), fundamental challenges persist with negative profitability metrics and high valuation multiples. The stock faces execution risks amid competitive genomics landscape, but operational improvements and testing volume growth provide potential catalysts for recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Oatly Group AB - ADR
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, Icecreams, among others. It caters to Sweden, Germany, United Kingdom, Netherlands, North America, Finland, and other markets.
Read more on OTLY →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
